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Case Report
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A B S T R A C T
We discuss two adult siblings who presented with symptoms of myalgia and rhabdomyolysis following exercise
with myoglobinuria; genetic testing conﬁrmed carnitine palmitoyltransferase II deﬁciency and resulted in in-
stitution of appropriate crisis management and dietary advice. We explore the phenotypic variability of this
commonest fatty oxidation defect that remains under-diagnosed in the adult population and provide clues for
early recognition and diagnosis.
1. History
The index patient was a 35-year old woman with a longstanding
history of tiredness after exercise since 12 years of age. She joined the
army aged 18-years of age and served for 12 years. During this period,
she noted frequent episodes of muscle aches, weakness and dark urine
following vigorous exercise. Her older brother aged 40-years was
asymptomatic until recently; however, following a dental procedure
under local anaesthetic (Lidocaine 1%), he developed episodes of se-
vere tiredness, muscle cramps associated with dark urine and was also
investigated further.
2. Examination
Both the siblings were well grown with normal neurological ex-
aminations.
3. Investigations
The index patient was noted to have an elevated creatine kinase as
high as 68,000 IU/L on one occasion and myoglobinuria. Plasma acyl-
carnitine analysis showed increases in C16 and C18 species with normal
free carnitine. The brother also showed slightly elevated CK at 348 IU/L
with a similar plasma acylcarnitine proﬁle.
In index patient: Plasma acylcarnitine proﬁle. Increased
concentration of the following acylcarnitines (μmol/L):
C0=27 (ref 15–53)
C2=7.44 (ref 5–27)
C16:1=0.19 (ref < 0.08)
C16= 0.86 (ref < 0.24)
C18:1=1.50 (ref < 0.28)
C18= 0.34 (< 0.10)
Normal free carnitine [i.e. C0] 27 μmol/L (ref 15–53).
In older sibling: Plasma acylcarnitine proﬁle:
C0=30.81 (ref 15–53)
C2=8.84 (ref 5–27)
C16:1=0.04 (ref < 0.08)
C16= 0.56 μmol/L (ref < 0.24)
C18:1=0.71 (ref < 0.28)
C18= 0.31 (< 0.10)
Normal free carnitine [C0] 31 μmol/L (ref 15–53).
4. Molecular testing
Genetic testing was undertaken at Sheﬃeld Diagnostic Genetics
Service, initially in the sister's genomic DNA, through targeted Sanger
sequencing for the two common pathogenic variants in PYGM:
https://doi.org/10.1016/j.ymgmr.2018.02.008
Received 26 January 2018; Received in revised form 23 February 2018; Accepted 24 February 2018
⁎ Corresponding author at: Sheﬃeld Clinical Genetics Service, Sheﬃeld Children's NHS Foundation Trust, Western Bank, Sheﬃeld S10 2TH, UK.
E-mail address: meena.balasubramanian@nhs.net (M. Balasubramanian).
0ROHFXODU*HQHWLFVDQG0HWDEROLVP5HSRUWV²
7KH$XWKRUV3XEOLVKHGE\(OVHYLHU,QF7KLVLVDQRSHQDFFHVVDUWLFOHXQGHUWKH&&%<1&1'OLFHQVHKWWSFUHDWLYHFRPPRQVRUJOLFHQVHV%<1&1'
7
c.148C>T, p.Arg50* and c.613G>A, p.Gly205Ser associated with
Glycogen storage disease type V (McArdle disease). Subsequent testing
showed she was heterozygous for the common c.338C>T,
p.Ser113Leu pathogenic variant in exon 3 of CPT2, and extended mu-
tation screening then identiﬁed a second, novel c.1665C>G,
p.His555Gln likely pathogenic variant, aﬀecting a highly conserved
amino acid position among acyltransferases, and supported by variant
eﬀect prediction software programs. This variant was not present in
population databases. Carrier testing of parents conﬁrmed that this
patient was a compound heterozygote. These results conﬁrmed the
clinical diagnosis of CPT II deﬁciency. Testing in the brother also
showed that he carried both these variants in CPT2.
5. Management
Following genetic diagnosis, both siblings were referred to the
metabolic service for management of their symptoms and dietary ad-
vice. Advice was provided regarding avoidance of fasting, excessive
exercise, modest dietary fat restriction and prescription of medium
chain triglycerides (Vitaﬂo MCT Procal) and Vitaﬂo SOS25 for emer-
gency use. An emergency regimen (www.bimdg.org.uk) was provided
for management of acute crises. Advice was also provided regarding
avoidance of medications including non-steroidal anti-inﬂammatory
drugs (especially ibuprofen for post-exercise muscle pain as this may
increase the likelihood of renal failure), seeking specialist advice prior
to general anaesthetic use; annual ﬂu vaccinations.
6. Outcome
For these siblings who presented with the late myopathic form of
CPT II deﬁciency, it has been crucial to make the correct diagnosis in
order to institute appropriate management.
7. Discussion
Carnitine palmitoyltransferase II deﬁciency (CPT II deﬁciency) is a
long-chain fatty-acid oxidation disorder and consists of three diﬀerent
clinical presentations: a lethal neonatal form, severe infantile form and
a more common myopathic form (which can be mild with manifesta-
tions from infancy to adulthood) [2]. The two severe forms have multi-
system involvement with liver failure, cardiomyopathy, seizures and
early lethality. The focus of this discussion is the milder, myopathic
form of CPT II deﬁciency which is the most common disorder of lipid
metabolism aﬀecting skeletal muscle but remains under-diagnosed due
to lack of understanding of its clinical presentation [Wieser et al. 6]
Genereview: https://www.ncbi.nlm.nih.gov/books/NBK1253/].
The myopathic form of CPT II deﬁciency should be suspected in
individuals presenting with recurrent attacks of muscle weakness and
myoglobinuria precipitated by certain drugs, prolonged exercise, and
episodes of fasting or stress [4]. They may also present with weakness
during such crises but generally there are no intercurrent signs of
myopathy. Males generally tend to be more severely aﬀected than fe-
males. There is usually a more than ﬁve-fold increase in serum CK levels
with elevation of C12 to C18 acylcarnitine on measurement of plasma
acylcarnitines.
Conﬁrmatory diagnosis is by identiﬁcation of disease-causing var-
iants in CPT2 through targeted testing [1]. In terms of genotype-phe-
notype correlation, missense pathogenic variants cause the myopathic
form with p.Ser113Leu accounting for 60% of pathogenic variants in
this form of the condition [5]. CPT2 pathogenic variants that result in
truncation of protein or mRNA degradation are more likely to be as-
sociated with the severe forms of the condition [6].
In this family, following identiﬁcation of the common pathogenic
p.Ser113Leu variant, extended screening identiﬁed the second, pre-
viously unreported variant: p.His555Gln; this variant aﬀects a highly
conserved amino acid; in silico analysis supports pathogenicity and not
present in population databases.
The myopathic form of CPT II deﬁciency is the commonest fatty
oxidation disorder aﬀecting muscle and the one most likely to cause
myoglobinuria. Consequently, if the clinical history includes “un-
explained” rhabdomyolysis, clinicians should have a low threshold to
perform plasma acylcarnitine analysis as a ﬁrst line investigation,
especially in the context of elevated CK. If this is suggestive, it is im-
portant to obtain conﬁrmatory genetic diagnosis as this informs man-
agement of this under-recognised condition. It is also important as
heterozygotes have occasionally been reported with a clinical pheno-
type, although they are more likely to only have a biochemical phe-
notype [3].
Management of myopathic CPT II deﬁciency is mainly focused on
preventing renal failure during a crisis and involves avoidance of
known triggers, reducing dietary long-chain fats, providing carnitine
and adequate hydration. It is important that these individuals have
specialist dietary advice and annual monitoring.
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